GERON CORP (GERN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
23/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseGERN / S&P -14.09% / 15.20% |
LoseGERN / S&P GERN unavailable / 15.00% |
LoseGERN / S&P -15.38% / 50.40% |
| 2026-Q11/3 |
WinGERN / S&P 12.88% / -4.33% |
LoseGERN / S&P GERN unavailable / 11.30% |
LoseGERN / S&P -47.62% / 27.70% |
| 2025-Q40/3 |
LoseGERN / S&P -3.65% / 2.65% |
LoseGERN / S&P GERN unavailable / 9.00% |
LoseGERN / S&P -51.85% / 13.40% |
| 2025-Q30/3 |
LoseGERN / S&P -2.84% / 8.12% |
LoseGERN / S&P GERN unavailable / 4.61% |
LoseGERN / S&P -62.50% / 13.45% |
| 2025-Q20/3 |
LoseGERN / S&P -11.32% / 10.94% |
LoseGERN / S&P GERN unavailable / 4.83% |
LoseGERN / S&P -63.89% / 10.63% |
| 2025-Q10/3 |
LoseGERN / S&P -55.08% / -4.27% |
LoseGERN / S&P GERN unavailable / 4.98% |
LoseGERN / S&P -40.00% / 10.57% |
| 2024-Q40/3 |
LoseGERN / S&P -22.03% / 2.41% |
LoseGERN / S&P GERN unavailable / 5.25% |
LoseGERN / S&P -18.18% / 6.15% |
| 2024-Q32/3 |
WinGERN / S&P 7.08% / 5.89% |
WinGERN / S&P 9199.68% / 5.89% |
LoseGERN / S&P -8.57% / 6.11% |
| 2024-Q22/3 |
WinGERN / S&P 28.48% / 4.28% |
WinGERN / S&P 205.11% / 5.38% |
LoseGERN / S&P -2.70% / 5.12% |
| 2024-Q11/3 |
WinGERN / S&P 56.40% / 10.56% |
LoseGERN / S&P 5.26% / 5.71% |
LoseGERN / S&P -0.00% / 5.59% |
| 2023-Q40/3 |
LoseGERN / S&P -0.47% / 11.69% |
LoseGERN / S&P -60.23% / 6.81% |
LoseGERN / S&P -10.81% / 7.78% |
| 2023-Q31/3 |
LoseGERN / S&P -33.96% / -3.27% |
LoseGERN / S&P -79.32% / 7.52% |
WinGERN / S&P 0.00% / -5.03% |
| 2023-Q22/3 |
WinGERN / S&P 47.93% / 8.74% |
LoseGERN / S&P -66.54% / 9.50% |
WinGERN / S&P 12.12% / -8.57% |
| 2023-Q11/3 |
LoseGERN / S&P -10.33% / 7.50% |
LoseGERN / S&P -64.18% / 10.77% |
WinGERN / S&P 0.00% / -15.69% |
| 2022-Q40/3 |
LoseGERN / S&P 3.42% / 7.56% |
LoseGERN / S&P -57.21% / 11.88% |
LoseGERN / S&P GERN unavailable / -17.99% |
| 2022-Q32/3 |
WinGERN / S&P 50.97% / -4.88% |
WinGERN / S&P 280.40% / 13.47% |
LoseGERN / S&P GERN unavailable / -1.41% |
| 2022-Q22/3 |
WinGERN / S&P 13.97% / -16.10% |
WinGERN / S&P 234.58% / 13.71% |
LoseGERN / S&P GERN unavailable / 11.04% |
| 2022-Q12/3 |
WinGERN / S&P 11.48% / -4.60% |
WinGERN / S&P 307.99% / 15.97% |
LoseGERN / S&P GERN unavailable / 42.23% |
| 2021-Q41/3 |
LoseGERN / S&P -10.95% / 11.03% |
WinGERN / S&P 450.59% / 15.00% |
LoseGERN / S&P GERN unavailable / 96.40% |
| 2021-Q30/3 |
LoseGERN / S&P -2.84% / 0.58% |
LoseGERN / S&P 7.75% / 10.77% |
LoseGERN / S&P GERN unavailable / 69.42% |
| 2021-Q20/3 |
LoseGERN / S&P -10.76% / 8.55% |
LoseGERN / S&P 1.26% / 6.58% |
LoseGERN / S&P GERN unavailable / 51.81% |
| 2021-Q10/3 |
LoseGERN / S&P -0.63% / 6.17% |
LoseGERN / S&P -25.71% / -1.06% |
LoseGERN / S&P GERN unavailable / 7.39% |
| 2020-Q40/3 |
LoseGERN / S&P -8.62% / 12.15% |
LoseGERN / S&P -45.00% / -3.72% |
LoseGERN / S&P GERN unavailable / -33.42% |
| 2020-Q30/3 |
LoseGERN / S&P -20.18% / 8.93% |
LoseGERN / S&P -43.67% / -2.04% |
LoseGERN / S&P GERN unavailable / -27.10% |
| 2020-Q21/3 |
WinGERN / S&P 83.19% / 20.54% |
LoseGERN / S&P -43.12% / -0.46% |
LoseGERN / S&P GERN unavailable / -27.11% |
| 2020-Q11/3 |
WinGERN / S&P -12.50% / -19.60% |
LoseGERN / S&P -43.48% / 3.47% |
LoseGERN / S&P GERN unavailable / -14.75% |
| 2019-Q40/3 |
LoseGERN / S&P 2.26% / 9.07% |
LoseGERN / S&P -56.85% / 5.36% |
LoseGERN / S&P GERN unavailable / 2.99% |
| 2019-Q30/3 |
LoseGERN / S&P -5.67% / 1.70% |
LoseGERN / S&P GERN unavailable / 5.02% |
LoseGERN / S&P GERN unavailable / 0.21% |
| 2019-Q20/3 |
LoseGERN / S&P -15.06% / 4.30% |
LoseGERN / S&P GERN unavailable / 6.64% |
LoseGERN / S&P GERN unavailable / 8.65% |
| 2019-Q11/3 |
WinGERN / S&P 66.00% / 13.65% |
LoseGERN / S&P GERN unavailable / 8.12% |
LoseGERN / S&P GERN unavailable / 14.29% |
| 2018-Q40/3 |
LoseGERN / S&P -43.18% / -13.52% |
LoseGERN / S&P GERN unavailable / 9.05% |
LoseGERN / S&P GERN unavailable / 18.23% |
| 2018-Q30/3 |
LoseGERN / S&P -48.69% / 7.71% |
LoseGERN / S&P GERN unavailable / 10.21% |
LoseGERN / S&P GERN unavailable / 19.06% |
| 2018-Q20/3 |
LoseGERN / S&P -19.29% / 3.43% |
LoseGERN / S&P GERN unavailable / 9.03% |
LoseGERN / S&P GERN unavailable / 14.46% |
| 2018-Q11/3 |
WinGERN / S&P 136.11% / -0.76% |
LoseGERN / S&P GERN unavailable / 7.68% |
LoseGERN / S&P GERN unavailable / 12.46% |
| 2017-Q40/3 |
LoseGERN / S&P -17.43% / 6.64% |
LoseGERN / S&P GERN unavailable / 7.03% |
LoseGERN / S&P GERN unavailable / 13.82% |
| 2017-Q30/3 |
LoseGERN / S&P -21.30% / 4.48% |
LoseGERN / S&P GERN unavailable / 5.68% |
LoseGERN / S&P GERN unavailable / 17.57% |
| 2017-Q21/3 |
WinGERN / S&P 22.03% / 3.09% |
LoseGERN / S&P GERN unavailable / 4.83% |
LoseGERN / S&P GERN unavailable / 17.74% |
| 2017-Q11/3 |
WinGERN / S&P 9.66% / 6.07% |
LoseGERN / S&P GERN unavailable / 3.67% |
LoseGERN / S&P GERN unavailable / 13.32% |
| 2016-Q40/3 |
LoseGERN / S&P -8.41% / 3.82% |
LoseGERN / S&P -83.06% / 2.09% |
LoseGERN / S&P GERN unavailable / 7.05% |
| 2016-Q30/3 |
LoseGERN / S&P -15.67% / 3.85% |
LoseGERN / S&P -82.69% / 0.20% |
LoseGERN / S&P GERN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | GERN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 9.29% | 20.78% |
| Annualized return | 9.29% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | GERN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 4.79% | 83.14% |
| Annualized return | 0.94% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | GERN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -43.96% | 319.30% |
| Annualized return | -5.63% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |